Puma Biotechnology Inc. (PBYI)
| Bid | 3.3 |
| Market Cap | 166.44M |
| Revenue (ttm) | 243.96M |
| Net Income (ttm) | 23.28M |
| EPS (ttm) | 0.62 |
| PE Ratio (ttm) | 5.41 |
| Forward PE | 5.09 |
| Analyst | Buy |
| Ask | 3.6 |
| Volume | 817,209 |
| Avg. Volume (20D) | 561,951.3 |
| Open | 3.53 |
| Previous Close | 3.58 |
| Day's Range | 3.34 - 3.64 |
| 52-Week Range | 2.23 - 6.06 |
| Beta | 1.08 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advance...
Analyst Forecast
According to 1 analyst ratings, the average rating for PBYI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 108.64% from the latest price.
Earnings Surprise
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial ResultsLOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m. PT/4:30 p.m. ET.
